©The Author(s) 2025.
World J Gastroenterol. Sep 14, 2025; 31(34): 109718
Published online Sep 14, 2025. doi: 10.3748/wjg.v31.i34.109718
Published online Sep 14, 2025. doi: 10.3748/wjg.v31.i34.109718
Table 2 Baseline and clinical data, n (%)
| Total (n = 301) | Colonoscopy findings | P value | Homocysteine | P value | |||||
| No polyps (n = 79) | Low-risk polyps (n = 54) | High-risk polyps (n = 107) | Adenocarcinoma | ≤ 15 (n = 213) | > 15 (n = 88) | ||||
| Age (years), median (IQR) | 63.0 (57.0-67.0) | 61.0 (55.0-65.0) | 61.0 (57.0-65.0) | 62.0 (58.5-67.0) | 69.0 (63.0-79.0) | < 0.0001 | 62.0 (57.0-67.0) | 64.0 (60.0-70.0) | 0.0046 |
| < 65 | 177 (58.8) | 55 (69.6) | 36 (66.7) | 65 (60.7) | 21 (34.4) | 0.0001 | 131 (61.5) | 46 (52.3) | 0.1767 |
| ≥ 65 | 124 (41.2) | 24 (30.4) | 18 (33.3) | 42 (39.3) | 40 (65.6) | 82 (38.5) | 42 (47.7) | ||
| Sex | 0.0001 | 0.0003 | |||||||
| Female | 132 (43.9) | 48 (60.8) | 29 (53.7) | 32 (29.9) | 23 (37.7) | 108 (50.7) | 24 (27.3) | ||
| Male | 169 (56.1) | 31 (39.2) | 25 (46.3) | 75 (70.1) | 38 (62.3) | 105 (49.3) | 64 (72.7) | ||
| Alcohol intaking | 73 (24.3) | 14 (17.7) | 16 (29.6) | 24 (22.4) | 19 (31.1) | 0.2162 | 49 (23.0) | 24 (27.3) | 0.5235 |
| Smoking | 63 (20.9) | 11 (13.9) | 14 (25.9) | 31 (29.0) | 7 (11.5) | 0.0139 | 40 (18.8) | 23 (26.1) | 0.2036 |
| Diabetes | 45 (15.0) | 12 (15.2) | 4 (7.4) | 15 (14.0) | 14 (23.0) | 0.1349 | 29 (13.6) | 16 (18.2) | 0.4049 |
| Hypertension | 118 (39.2) | 28 (35.4) | 17 (31.5) | 47 (43.9) | 26 (42.6) | 0.3735 | 80 (37.6) | 38 (43.2) | 0.4359 |
| Obesity | 95 (31.6) | 26 (32.9) | 19 (35.2) | 33 (30.8) | 17 (27.9) | 0.8481 | 67 (31.5) | 28 (31.8) | 1.0000 |
| Dyslipidemia | 139 (46.2) | 40 (50.6) | 28 (51.9) | 47 (43.9) | 24 (39.3) | 0.4411 | 104 (48.8) | 35 (39.8) | 0.1916 |
| Coronaropathy | 23 (7.6) | 5 (6.3) | 3 (5.6) | 8 (7.5) | 7 (11.5) | 0.6598 | 14 (6.6) | 9 (10.2) | 0.3970 |
| Chronic kidney injury | 11 (3.7) | 2 (2.5) | 1 (1.9) | 4 (3.7) | 4 (6.6) | 0.5979 | 4 (1.9) | 7 (8.0) | 0.0168 |
| Family history of CRC | 13 (4.3) | 4 (5.1) | 3 (5.6) | 5 (4.7) | 1 (1.6) | 0.7309 | 9 (4.2) | 4 (4.5) | 1.0000 |
| Colonoscopy findings | No significant connection | < 0.0001 | |||||||
| No polyps | 79 (26.2) | 79 (100.0) | - | - | - | 66 (31.0) | 13 (14.8) | ||
| Low-risk polyps | 54 (17.9) | - | 54 (100.0) | - | - | 46 (21.6) | 8 (9.1) | ||
| High-risk polyps | 107 (35.5) | - | - | 107 (100.0) | - | 73 (34.3) | 34 (38.6) | ||
| Adenocarcinoma | 61 (20.3) | - | - | - | 61 (100.0) | 28 (13.1) | 33 (37.5) | ||
| Medication associated with increased Hcy | 118 (39.2) | 35 (44.3) | 19 (35.2) | 40 (37.4) | 24 (39.3) | 0.7109 | 81 (38.0) | 37 (42.0) | 0.6034 |
| Medication associated with decreased Hcy | 15 (5.0) | 4 (5.1) | - | 6 (5.6) | 5 (8.2) | 0.1920 | 5 (2.3) | 10 (11.4) | 0.0023 |
| Homocysteine (µmol/L), median (IQR) | 12.5 (10.8-15.5) | 11.5 (9.74-13.5) | 11.8 (10.8-13.3) | 12.5 (10.9-16.0) | 15.3 (12.4-19.3) | < 0.0001 | 11.3 (10.1-12.6) | 17.7 (16.1-21.8) | n/c |
| Homocysteine | < 0.0001 | n/c | |||||||
| ≤ 15 | 213 (70.8) | 66 (83.5) | 46 (85.2) | 73 (68.2) | 28 (45.9) | 213 (100.0) | - | ||
| > 15 | 88 (29.2) | 13 (16.5) | 8 (14.8) | 34 (31.8) | 33 (54.1) | - | 88 (100.0) | ||
- Citation: Cano FX, Duque JM, Seoane L, Puga-Tejada M, Espinoza de los Monteros A, Bermeo P, Junquera E, Pérez D, Martin-Delgado J, Santelli M, Pérez C, Pérez Rivera FJ. Serum homocysteine-based traffic light triage colonoscopy screening in colorectal cancer at-risk patients: A prospective cohort study. World J Gastroenterol 2025; 31(34): 109718
- URL: https://www.wjgnet.com/1007-9327/full/v31/i34/109718.htm
- DOI: https://dx.doi.org/10.3748/wjg.v31.i34.109718